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OBJECTIVES The present study was designed to test the efficacy of paclitaxel added to the contrast agent
iopromide in the prevention of restenosis.
BACKGROUND Contrast media adhere to the coronary vessel wall for some seconds after injection. Such a
layer of contrast agent could serve as a matrix for antiproliferative drugs.
METHODS Thirty-four stents were implanted into the left anterior descending and circumflex coronary
arteries of 17 pigs, using a 1.2:1.0 overstretch ratio. The unsupplemented contrast agent
iopromide-370 was used as a control; the treatment groups were treated with 80 ml
intracoronary iopromide plus either 100 or 200 mol/l paclitaxel, or 80 ml intravenous
iopromide plus 200 mol/l paclitaxel. Quantitative angiography and histomorphometry were
used to assess comparable baseline parameters between the treatment groups.
RESULTS A short time incubation (3 min) almost completely inhibited vascular smooth muscle cell
proliferation, sustained for up to 12 days. Whereas intravenous paclitaxel had no effect,
intracoronary application of paclitaxel reduced the diameter stenosis from 55  13% to 29 
18% and 13  12%. Late lumen loss dropped from 1.94  0.35 mm under the control
condition to 1.19  0.55 mm with 100 mol/l paclitaxel and to 0.82  0.54 mm with 200
mol/l paclitaxel. Histomorphometry revealed a corresponding dose-dependent reduction of
the neointimal area and restenosis by intracoronary iopromide paclitaxel. Assessment of left
ventricular function and myocardial histology revealed no adverse effects of intracoronary
paclitaxel application.
CONCLUSIONS This study provides evidence that intracoronary application of a taxane dissolved in a contrast
medium profoundly inhibits in-stent restenosis. This novel, widely feasible approach may be
suited for the prevention of restenosis in a broad spectrum of interventional treatment
regimens. (J Am Coll Cardiol 2003;42:1415–20) © 2003 by the American College of
Cardiology Foundation
Restenosis prevention continues to be a challenging task.
Preclinical and clinical trials have shown that drug-eluting
stents (DES) suppress neointimal proliferation (1,2).
However, the efficacy and safety have not been ensured in
all clinical settings, with remaining uncertainties in, for
example, diabetics, acute coronary syndromes, bifurcation
lesions, small vessels, or in-stent restenosis. Non–stent-
based local delivery of antiproliferative drugs may offer
additional flexibility and efficacy in the entire range of
applications and may also affect vessel areas beyond the
immediate stent coverage, which could be of special interest
for small and tortuous vessels. Furthermore, healing and
re-endothelialization of stent struts bare of antiproliferative
agents may be facilitated.
Contrast agents delineate the contour of coronary arteries
for some seconds after injection due to a low local flow
velocity. We assume that such a layer of contrast agent
adherent to the endothelium could provide a matrix for
antiproliferative drugs. A key requirement for such a mode
of drug delivery would have to be a rapid uptake by the
vessel wall to achieve growth inhibition. Antiproliferative
taxanes such as paclitaxel are highly lipophilic and bind
tightly to cellular tissue (3), resulting in local retention at the
site of delivery (4,5). The new approach of combining
paclitaxel with a contrast agent is attractive because it does
not require a particular delivery device or a specified stent.
The aim of the present study was to test the efficacy of
different concentrations of paclitaxel added to the contrast
agent iopromide for restenosis inhibition and to evaluate
potential cardiotoxic effects of intracoronary administration.
METHODS
Study drugs. The contrast agent iopromide-370 (Ultravist,
Schering AG, Berlin, Germany) was used alone or as a
solvent for paclitaxel in this investigation of cell culture
experiments and in porcine coronary studies. Paclitaxel is
widely used in antineoplastic chemotherapy (3).
For in vitro studies, iopromide-370 was diluted with
water for injection to make a 40.5% vol/vol solution, which
is isosmotic. Paclitaxel was dissolved in the contrast agent,
which contained 1% vol/vol ethanol and was further diluted
1:1 with cell culture medium to a final taxane concentration
of 1.46 mol/l (“low concentration”) or 14.6 mol/l (“high
concentration”) in the incubation solution.
For the porcine efficacy studies, iopromide (Ultravist) was
used in group I (control). Group II was injected with
additional intravenous iopromide containing 200 mol/l
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paclitaxel at the same dose and time schedule as for the
intracoronary contrast agent. Groups III and IV received
intracoronary iopromide containing 100 and 200 mol/l
paclitaxel, respectively. In the tissue uptake study, 200
mol/l paclitaxel in Ultravist-370 was used for coronary
angiography. The dose was kept constant at 80 ml per
animal, with the exception of group II, which received an
additional 80 ml intravenously.
Cell culture experiments. Bovine aortic smooth muscle
cells (passages 3 to 10) were cultured using Dulbecco’s
minimal essential medium (DMEM) supplemented with
10% fetal bovine serum (FBS). Cells were seeded at 10,000/
cm2 and incubated for 3, 10, or 60 min with 0.9% saline
(control) and iopromide supplemented with paclitaxel. The
supernatant was removed; cells were washed with 0.9%
saline and cultured with DMEM plus 10% FBS. At days 0,
3, 6, 9, and 12, cell counts were assessed.
Animal studies. All experiments were conducted in accor-
dance with the guidelines for animal experiments set forth
by the local animal protection committee. Domestic pigs
were presedated with an intramuscular injection of ketamine
and xylazine. Venous access was provided and anesthesia
initiated by intravenous injection of propofol, followed by
orotracheal intubation, maintained with 1.0 to 2.0 vol%
isoflurane, 70 vol% N2O, and 30 vol% oxygen. All animals
received 5,000 IU heparin, 250 mg aspirin intravenously
(Aspisol, Bayer AG, Germany), and intracoronary nitro-
glycerin. The coronary arteries were imaged using a stan-
dard angiographic technique via the right carotid artery.
Target segments were selected in the left anterior descend-
ing (LAD) and circumflex (Cx) coronary arteries.
Paclitaxel concentration in tissue and plasma. To deter-
mine the paclitaxel plasma level and uptake of paclitaxel into
the vessel wall and various tissues, nine domestic pigs
(26.4  0.9 kg body weight) received stainless-steel stents
into the LAD and Cx arteries (diameter 3.5 mm, length
13 mm; MultiLink Duet, Guidant, Germany) while inject-
ing 80 ml iopromide containing 200 mol/l paclitaxel as
intermittent boluses. Blood samples were taken to deter-
mine the time course of systemic paclitaxel concentration.
After 10 min, 2 h, and 24 h, stented segments, coronary
artery segments 1.5 cm proximal and distal from the stented
portion, and myocardial tissue about 5 mm apart from the
LAD or Cx without major branches of the coronary arteries,
respectively, were dissected. Additionally, three segments
from the right coronary artery were studied. Paclitaxel was
extracted from homogenized tissue samples by dimethyl
sulfoxide and from plasma samples with docetaxel as an
internal standard by ethyl acetate. Samples were analyzed by
high-performance liquid chromatography using Waters
Symmetry column C-18, 5 mol/l, 25 cm  4.6 mm, and
acetonitrile/0.005 potassium phosphate buffer pH 3.5 (40:
60, paclitaxel retention time 35 to 45 min; or 55:45,
paclitaxel retention time ca 7.5 min), detection by ultraviolet
photometry at 230 nm.
Restenosis study. Stainless-steel stents (diameter 3.0 to
3.5 mm, length 16 mm; FlexMaster, Jomed, Rangendingen,
Germany) were implanted into the LAD and Cx arteries in
17 domestic pigs (weight 25.8  1.5 kg). The animals were
randomized to control (unsupplemented contrast agent
iopromide-370), 80 ml intracoronary iopromide plus either
100 or 200 mol/l paclitaxel, or 80 ml intravenous iopro-
mide plus 200 mol/l paclitaxel. The route of study drug
administration was unblinded, but all data analyses were
blinded.
Prophylactic intramuscular streptomycin and penicillin
were given. Aspirin, 100 mg, and ticlopidine, 250 mg/day,
were orally administered starting three days before the
procedure and continued for 28 days. Follow-up angiogra-
phy was performed 28 days later, and the animals were
subsequently sacrificed using 3 mol/l KCl under deep
anesthesia. Hearts were rapidly excised; the coronary system
flushed with 0.9% saline; and the arteries fixed by perfusion
with 4% buffered formalin under physiologic pressure and
overnight immersion. The target vessel segments were then
dissected, and samples for histologic analysis were obtained.
Six samples of myocardium were taken: three from the left
myocardium exposed to the selective contrast medium
injections and three from the right heart. Histopathologic
evaluation was performed by the Laboratory of Pharmacol-
ogy and Toxicology KG (Hamburg, Germany).
Coronary imaging was done using a Philips PolyArc
fluoroscope connected to a digitizer using an Apple Macin-
tosh Power PC. The CAAS II System (Pie Medical, the
Netherlands) was used for quantitative coronary analysis by
two experienced cardiologists blinded to the treatment
groups. Discrepancies were resolved by mutual consensus.
Left ventricular levocardiography was used to evaluate
measures of left ventricular function from the angiography
at 28-day follow-up.
Histologic analysis. Stented coronary arteries were dis-
sected from the formalin-fixed hearts and immersed in
methylmethacrylate (Merck, Darmstadt, Germany). Three
representative cross sections per stent were separated from
the blocks with a coping saw, polished, and glued on acrylic
plastic slides. Final specimens were stained by the van
Gieson and hematoxylin-eosin technique. After digitaliza-
tion, histomorphometric measurements were taken with the
NIH image program (PC version “Scion Image,” Scion
Corp., Frederick, Maryland). The evaluated parameters
were the lumen diameter, external elastic lamina (EEL)
diameter, maximal neointimal thickness, EEL area, lumen
Abbreviations and Acronyms
CM  contrast medium
Cx  circumflex artery
DES  drug-eluting stent
DMEM  Dulbecco’s minimal essential medium
EEL  external elastic lamina
FBS  fetal bovine serum
LAD  left anterior descending coronary artery
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area, and neointimal area. The injury score was assessed as
previously described by Schwartz et al. (6).
Statistical analysis. Histomorphometric variables of the
three cross-sectional planes were averaged to obtain a mean
value per stent. Continuous variables of quantitative coro-
nary angiography and histomorphometry were compared by
analysis of variance (one-way repeated measures, 3 or 4
factors) using the software SPSS version 11.0 for Windows
(SPSS Inc., Chicago, Illinois). Data are presented as the
mean value  SD.
RESULTS
Cell culture experiments. Addition of paclitaxel (1.46 or
14.6 mol/l) to iopromide for 3, 10, and 60 min to the cell
culture medium significantly inhibited vascular smooth
muscle cell proliferation in a concentration-dependent man-
ner. Incubation times of 10 and 3 min with a concentration
of 14.6 mol/l paclitaxel exhibited the same efficacy as the
60-min incubation (Fig. 1).
Intracoronary paclitaxel uptake. Coronary artery seg-
ments of 1.5 cm length were prepared 5 min, 2 h, and
24 h after catheterization to quantify the paclitaxel concen-
tration, as depicted in Table 1. Initial concentrations mea-
suring 10 to 15 mol/l were comparable for all LAD
segments (proximal, stented, distal; Table 1). Concentra-
tions in the Cx segments were about half as high, whereas
samples taken from the right coronary artery, which were
not directly perfused by the contrast medium (CM)-
paclitaxel preparation, reached about 1 mol/l. Two hours
after stent implantation, paclitaxel concentrations in the
samples from the LAD and Cx were about 2 mol/l. This
indicates a half-life of paclitaxel in the LAD of about 45
min and in Cx of 85 min. Twenty-four hours after CM
injection and stent implantation, paclitaxel was still detected
in the LAD of two of three pigs, whereas it was below the
detection limit of 0.4 mol/l in half of the samples taken
from the Cx. The paclitaxel concentration in plasma was
0.46  0.22 mol/l (n  9) immediately following the last
injection, decreasing to 0.074  0.025 and 0.039  0.018
mol/l after 30 or 60 min, respectively (n  3 each).
Restenosis study. In one pig, the interventional procedure
was complicated by a flow-limiting dissecting, resulting in
total occlusion of the Cx. The animal survived; however, it
was excluded from further analysis. The remaining 16 pigs
with 32 stents recovered and survived the follow-up period.
Baseline data were comparable between the treatment
groups. Histologic analysis revealed sufficient stent expan-
sion. The coronary artery sizes by the EEL diameter and
area were similar in all groups. After 28 days, there were no
significant angiographic or histomorphometric differences
between group I (iopromide) and group II (intravenous
application of iopromide paclitaxel). The intracoronary
iopromide paclitaxel groups showed a marked reduction of
the parameters characterizing in-stent restenosis, compared
with the control group (Table 2, Fig. 2). When comparing
the angiographic measurements by the parameters listed in
Figure 1. Effects of different concentrations and incubation times (60, 10, and 3 min) of iopromide (75 mg/ml iodine) or iopromide plus paclitaxel (1.46
or 14.6 mol/l) as the final concentration in the cell culture medium. Bovine aortic smooth muscle cells (passages 3 to 10) were seeded at 10,000/cm2,
cultured with DMEM plus 10% FBS; cell counts were taken on days 0, 3, 6, 9 and 12. *p  0.05 vs. control; n  50.
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Table 2, there was a significant reduction of restenosis.
High-dose intracoronary iopromide paclitaxel led to a re-
duction of the neointimal area by 56% and maximal neoin-
timal thickness by 62% (Table 3). Despite the marked
reduction of neointimal proliferation, covering of stent
struts with a thin layer of neointima was ensured in all
samples.
Myocardial tolerance. After 28 days, there were no
differences in parameters characterizing global and local
left ventricular ejection fraction between the treatment
groups. Histopathology did not reveal any treatment-
related findings, but only incidental inflammatory re-
actions, vessel dilation, or perivascular edema in tissue
samples from the left and right myocardium in all treatment
groups.
DISCUSSION
Coronary stents coated with antiproliferative agents such as
sirolimus or paclitaxel have shown promising antirestenotic
effects in clinical trials (2). However, antiproliferative effects
are potentially restricted to the stented area, probably
resulting in reduced protection of segments proximal and
distal to the stent. Efficacy and safety have not been entirely
defined in all possible clinical settings, especially in patients
at increased risk of restenosis. Furthermore, concerns have
been raised that such drug-releasing stents, while effective,
may (similar to radiation) be prone to sudden thrombotic
occlusion (7), delayed restenosis (8), or late malapposition
(9). Polymeric matrixes on the stent embedding the anti-
proliferative drug itself could induce inflammation and
thrombosis (10). Incomplete healing of stent struts may
jeopardize the outcome (11).
Non–stent-based local delivery of antiproliferative drugs
may offer additional flexibility in the range of applications
and may access vessel areas outside the immediate coverage
of stents. Because stent struts are not the direct source of the
drug, healing may be facilitated.
The new concept using contrast media as a matrix for
antiproliferative drugs simply employs standard coronary
angiography. The hydrophobic paclitaxel exerts preferential
tissue binding, allowing for effective convection and diffu-
Table 1. Paclitaxel Concentration in 15-mm Segments of Coronary Arteries at Various Times
After the Injection of 80 ml Iopromide-370 With 200 mol/l Paclitaxel in the LAD and Cx of
Nine Pigs
Paclitaxel Concentration
5 min After Last
CM Injection
2 h After Last
CM Injection
24 h After Last
CM Injection
mol/l n mol/l n mol/l n
LAD
Stented segment 12.2  0.9 3 1.39  0.35 3 0.67  0.73 3 (1)
Proximal segment 13.3  3.1 3 2.73  0.92 3 0.58  0.52 3 (1)
Distal segment 12.2  1.2 3 2.73  0.92 3 0.55  0.52 3 (1)
Cx
Stented area 5.5  1.3 3 1.66  0.24 3 0.57  0.64 3 (1)
Proximal segment 3.8  0.4 3 2.02  0.16 2 0.32 3 (2)
Distal segment 9.1  2.5 3 3.17  0.78 3 0.21 3 (2)
Right coronary artery
(untreated control)
1.2  1.4 8 1.06  0.57 9 0.32  0.60 9 (6)
Data are presented as the mean value  SD. Numbers in parentheses indicate the number of samples below the detection limit
of 0.4 mol/l. Extraction from homogenized tissue samples by DMSO; analyzed by HPLC. Concentrations below the
detection limit were set at 0.00 mol/l, and included in the calculation of mean values.
CM  contrast medium; Cx  circumflex artery; LAD  left anterior descending coronary artery.





200 mol/l (n  10)
Intracoronary
Iopromide Paclitaxel
100 mol/l (n  10)
Intracoronary
Iopromide Paclitaxel
200 mol/l (n  10) p Value
Baseline angiography
Reference diameter (mm) 2.59  0.22 2.83  0.19 2.54  0.25 2.65  0.29 0.141
Stent diameter (mm) 3.19  0.11 3.40  0.10 3.15  0.23 3.25  0.19 0.039
Overstretch ratio 1.24  0.08 1.21  0.08 1.23  0.09 1.25  0.09 0.865
28-Day follow-up angiography
Minimal lumen diameter (mm) 1.26  0.29 1.16  0.37 1.96  0.61 2.40  0.40 0.001
Diameter stenosis (%) 55  13 59  12 29  18 13  12 0.001
Late loss (mm) 1.94  0.34 2.25  0.35 1.19  0.55 0.82  0.54 0.001
Reference diameter, stent diameter, and overstretch ratio (stent diameter/reference diameter) at baseline angiography. Minimal lumen diameter, diameter stenosis, and late lumen
loss (stent diameter at baseline  minimal lumen diameter at control) after 28-day angiography. Data are presented as the mean value  SD.
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sion into the arterial wall (4,12). However, competitive
binding (e.g., by albumin and other plasma proteins) ham-
pers paclitaxel accumulation (12). Therefore, plasma con-
centrations of paclitaxel sufficient to inhibit restenosis in the
peripheral circulation would probably reach toxic levels (13).
The presented in vitro experiments indicate that short
contact times with iopromide paclitaxel induce an almost
complete inhibition of vascular smooth muscle cell prolif-
eration. This is in agreement with our in vivo data showing
direct pharmacokinetic evidence for uptake of the active
compound in the vessel wall of opacified arteries and
adjacent tissue at concentrations in the range of 3 to 15
mol/l, which are similar to those effective in cell culture
experiments. Vessel segments proximal and distal to the
stented area were treated with concentrations identical to
those of the vessel covered by the stent. Consequently, based
on the long-lasting action of paclitaxel on cell growth and
the fast uptake of the compound in the vessel wall, reste-
nosis development was prevented. Notably, inhibition of
neointimal growth is comparable to that achieved with DES
(1,8).
Functional and histologic analysis excluded adverse effects
on the myocardium. In the clinical setting, application of 60
to 100 ml contrast agent containing 100 to 200 mol/l
paclitaxel would translate into a total dosage of 5 to 17 mg
paclitaxel per patient. This resembles only 2% to 6% of a
single dose applied in tumor therapy, although the initial
intracoronary taxane concentration during bolus application
is substantially higher than plasma levels during cancer
therapy (3). Plasma concentrations in pigs reached about
one-tenth the concentrations measured in patients during
tumor therapy lasting for a very short time.
Conclusions. This novel non–stent-based but vessel wall–
directed treatment regimen, applying paclitaxel in contrast
media, could be an efficacious, nonexpensive, and facile
strategy to prevent restenosis.
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Figure 2. Histologic analysis of stented porcine coronary arteries after 28 days. Control (left), 100 mol/l intracoronary iopromide paclitaxel (middle), and
200 mol/l intracoronary iopromide paclitaxel (right). Stented coronary arteries were dissected from the formalin-fixed hearts, immersed in
methylmethacrylate, and separated from the blocks with a coping saw, polished, and glued on acrylic plastic slides. Specimens were stained by the
hematoxylin-eosin technique.
Table 3. Histomorphometry of Stented Porcine Coronary Arteries After 28 Days
Control
Iopromide Paclitaxel
pic 100 mol/l ic 200 mol/l
n 16 10 6
Injury score 0.87  0.12 0.88  0.15 0.92  0.07 0.723
EEL area (mm2) 6.03  1.37 6.14  0.81 5.51  0.19 0.516
Luminal area (mm2) 2.33  0.76 2.94  1.11 3.78  0.44 0.004
Area stenosis (%) 59  13 51  17 31  10 0.001
Neointimal area (mm2) 3.69  1.38 3.19  1.17 1.73  0.62 0.008
Maximal neointimal thickness (mm) 0.77  0.39 0.50  0.23 0.29  0.24 0.011
Injury score, external elastic lamina (EEL) area, luminal area, area stenosis, neointimal area, and maximal neointimal thickness.
Histomorphometric measurements of the three cross-sectional planes were averaged to obtain a mean value per stent.
1419JACC Vol. 42, No. 8, 2003 Scheller et al.
October 15, 2003:1415–20 Iopromide Paclitaxel and Restenosis Prevention
REFERENCES
1. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating
inhibits neointimal hyperplasia at 4 weeks in a porcine model of
coronary restenosis. Circulation 2001;103:2289–95.
2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison
of a sirolimus-eluting stent with a standard stent for coronary revas-
cularization. N Engl J Med 2002;346:1773–80.
3. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med
1995;332:1004–14.
4. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution
and deposition. Circ Res 2000;86:879–84.
5. Seong HJ, Wientjes MG, Au JLS. Determinants of paclitaxel uptake,
accumulation and retention in solid tumors. Invest New Drugs
2001;19:113–23.
6. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the
proportional neointimal response to coronary artery injury: results in a
porcine model. J Am Coll Cardiol 1992;19:267–74.
7. Costa MA, Sabate M, van der Giessen WJ, et al. Late coronary
occlusion after intracoronary brachytherapy. Circulation 1999;100:
789–92.
8. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus
reduces neointimal formation in a porcine coronary model. Circulation
2001;104:1188–93.
9. Kozuma K, Costa MA, Sabate M, et al. Late stent malapposition
occurring after intracoronary beta-irradiation detected by intravascular
ultrasound. J Invasive Cardiol 1999;11:651–5.
10. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked
inflammatory sequelae to implantation of biodegradable and nonbio-
degradable polymers in porcine coronary arteries. Circulation 1996;94:
1690–7.
11. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local
delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:
473–9.
12. Lovich MA, Creel CJ, Hong K, et al. Carrier proteins fetermine local
pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci
2001;90:1324–35.
13. Kolodgie FD, John M, Khurana C, et al. Sustained reduction of
in-stent neointimal growth with the use of a novel systemic nanopar-
ticle paclitaxel. Circulation 2002;106:1195.
1420 Scheller et al. JACC Vol. 42, No. 8, 2003
Iopromide Paclitaxel and Restenosis Prevention October 15, 2003:1415–20
